We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+18.5%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
+$31.2M
Cap. Flow
+$169M
Cap. Flow %
8.75%
Top 10 Hldgs %
45.68%
Holding
151
New
31
Increased
40
Reduced
42
Closed
31

Top Buys

Rank Stock Value
1
ENSG icon
The Ensign Group
ENSG
+$104M
2
EHC icon
Encompass Health
EHC
+$86.2M
3
CTRE icon
CareTrust REIT
CTRE
+$42.1M
4
UNH icon
UnitedHealth
UNH
+$19M
5
INSM icon
Insmed
INSM
+$18.1M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$68.9M
2
NTRA icon
Natera
NTRA
+$44.5M
3
DOC icon
Healthpeak Properties
DOC
+$32.5M
4
AVTR icon
Avantor
AVTR
+$23.3M
5
QGEN icon
Qiagen
QGEN
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.53%
2 Real Estate 5.59%
3 Miscellaneous 4.84%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
101
Revolution Medicines
RVMD
$45B
$1.3M 0.07%
+6,943
New +$1.01M
SVRA icon
102
Savara
SVRA
$1.1B
$1.26M 0.07%
204,428
-179,836
-47% -$965K
SRZN icon
103
Surrozen
SRZN
$268M
$1.24M 0.06%
47,777
-10,847
-19% -$298K
INO icon
104
Inovio Pharmaceuticals
INO
$148M
$1.14M 0.06%
1,035,360
– –
PLRX icon
105
Pliant Therapeutics
PLRX
$71.8M
$1.02M 0.05%
891,425
– –
HELP
106
Cybin Inc
HELP
$893M
$968K 0.05%
+146,403
New +$732K
ODTX
107
Odyssey Therapeutics
ODTX
$1.38B
$929K 0.05%
+49,658
New +$871K
ENGN icon
108
enGene Therapeutics
ENGN
$122M
$812K 0.04%
469,584
-40,959
-8% -$167K
BCYC
109
Bicycle Therapeutics
BCYC
$301M
$809K 0.04%
190,715
– –
LPCN icon
110
Lipocine
LPCN
$20.2M
$755K 0.04%
294,989
– –
RLMD icon
111
Relmada Therapeutics
RLMD
$473M
$645K 0.03%
93,192
-184,707
-66% -$1.29M
EHTH icon
112
eHealth
EHTH
$31.7M
$603K 0.03%
404,854
+183,939
+83% +$308K
ATAI icon
113
AtaiBeckley Inc
ATAI
$2.74B
$540K 0.03%
+102,430
New +$431K
AKBA icon
114
Akebia Therapeutics
AKBA
$270M
$487K 0.03%
+427,095
New +$508K
SSII
115
SS Innovations International
SSII
$683M
$457K 0.02%
110,157
– –
ASMB icon
116
Assembly Biosciences
ASMB
$745M
$454K 0.02%
16,510
-24,379
-60% -$664K
RVP icon
117
Retractable Technologies
RVP
$21.3M
$418K 0.02%
580,919
– –
SLQT icon
118
SelectQuote
SLQT
$94.7M
$269K 0.01%
319,788
-37,873
-11% -$34.5K
GHRS icon
119
GH Research
GHRS
$1.94B
$233K 0.01%
+8,672
New +$181K
AVTX icon
120
Avalo Therapeutics
AVTX
$1.03B
$185K 0.01%
+10,000
New +$158K
AGIO icon
121
Agios Pharmaceuticals
AGIO
$1.98B
– –
-200,000
Closed -$6.77M
AIRS icon
122
AirSculpt Technologies
AIRS
$201M
– –
-74,139
Closed -$210K
AVTR icon
123
Avantor
AVTR
$10.1B
– –
-2,974,287
Closed -$23.3M
BVS icon
124
Bioventus
BVS
$961M
– –
-159,110
Closed -$1.45M
CNC icon
125
Centene
CNC
$33.1B
– –
-111,652
Closed -$3.66M
3 4
5
6 7

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Eversept Partners held 151 positions worth $1.93B, up 1.6% from $1.9B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Eversept Partners deployed $169M of net new capital in Q2 2026, opening 31 new positions and adding to 40 existing holdings. Its largest new stake was CareTrust REIT: 1,072,015 shares worth $43.3M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 74% a quarter earlier, followed by Real Estate and Miscellaneous.

On the sell side, the largest reduction was GSK, an estimated $68.9M trimmed.

  • Eversept Partners's largest Q2 2026 buy was CareTrust REIT: 1,072,015 shares worth $43.3M.
  • Eversept Partners added most to The Ensign Group in Q2 2026, an estimated $104M increase.
  • Eversept Partners's biggest Q2 2026 reduction was GSK, cutting an estimated $68.9M.
  • Eversept Partners fully exited Healthpeak Properties in Q2 2026, selling an estimated $32.5M.
  • Eversept Partners's ten largest holdings make up 46% of its $1.93B portfolio in Q2 2026.
  • Eversept Partners opened 31 new positions and closed 31 in Q2 2026.
  • Eversept Partners's portfolio value rose 1.6% quarter-over-quarter to $1.93B.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.